This represents a $1.70 dividend on an annualized basis and a dividend yield of 1.75%. Its down -0.10, from 1.1 in 2015Q4.
Advertisement
E I Du Pont De Nemours And Co (NYSE:DD) went down -0.10% during trading on 8/24/2016, hitting $70.69. 2,939,121 shares of the company were exchanged. Sold All: 68 Reduced: 554 Increased: 599 New Position: 84.
For the fiscal year ended 2017 CVS Health Corporation (NYSE:CVS) is estimated to post an EPS $1.72 as of 20160823, according to Zacks. During the same period in the previous year, the company posted $1.19 earnings per share. The Company operates through three business segments: Pharmacy Services, Retail Pharmacy and Corporate.
About 400 shares traded hands. It has underperformed by 12.84% the S&P500.
Traders are getting increasingly bearish on CVS Health Corporation (CVS), as can be seen in the addition of short positions from 11,350,095 on Jul 29, 2016, to 11,599,395 on August 15, 2016. The formula to calculate ratio is stock’s latest price/ per share earnings. Credit Agricole S A now owns 2,492,231 shares of the pharmacy operator’s stock worth $258,521,000 after buying an additional 1,320,987 shares during the period.
Monsanto confirmed it remains on track to be at the low end of its $3.36 to $4.14 as-stated 2016 full-year guidance range and at the low end of its ongoing EPS 2016 full-year guidance range of $4.40 to $5.10. Clearbridge Investments LLC boosted its stake in CVS Health Corporation by 36.2% in the fourth quarter. The Pharmacy Services segment provides a range of pharmacy benefit management (PBM) services and operates under the CVS/caremark Pharmacy Services, Novologix and Navarro Health Services names. “CVS Health Corporation, formerly known as CVS Caremark Corporation, is headquartered in Woonsocket, Rhode Island”.
Other Hedge Funds, Including, Compton Capital Management Inc Ri reduced its stake in CVS by selling 780 shares or 2.7% in the most recent quarter. The Illinois-based Dsc Advisors L.P. has invested 9.36% in the stock.
Advertisement
A number of Reuters analysts recently commented on the stock. 0 analysts hold “Sell” rating for the stock. The lowest target is $104 while the high is $123. The stock’s weekly volatility was 18.17% and the RSI amounts to 44.63. The average forecast of sales for the year ending Dec 16 is $24.84B by 16 analysts. Finally, Mizuho restated a “buy” rating and issued a $108.00 price objective (down from $117.00) on shares of CVS Health Corporation in a research note on Thursday, June 23rd. Robert W. Baird initiated CVS’s stock on a January 22. Macquarie restated an “outperform” rating and set a $115.00 price target on shares of CVS Health Corporation in a research report on Thursday, May 5th. FBR & Co restated a “buy” rating on shares of CVS Health Corporation in a research report on Saturday, May 14th.
